GE offers low dose breakthrough in Canada
TORONTO – GE Healthcare announced the introduction of a breakthrough Computed Tomography (CT) image reconstruction technology, called Veo, in Canada. The industry’s first Model-based Iterative Reconstruction (MBIR) technique, Veo is designed to help physicians deliver accurate diagnoses by enabling high CT image quality at significantly lower dose.
When compared to previous reconstruction methods, Veo’s capabilities “change the rules” of CT imaging by applying revolutionary new modeling techniques to potentially deliver lower noise, increased resolution, improved low contrast detectability and fewer artifacts. Already available in Europe and much of Asia, Veo is now available in Canada on the GE Discovery CT750 HD system. It is not yet available for sale in the United States.
Responding to radiologists’ demand for maximum CT image clarity and optimized low dose for their patients, Veo represents a powerful new tool that can help physicians more clearly visualize anatomy in order to deliver informed, accurate and confident diagnoses.
“The recent release of Veo in Canada offers radiologists the opportunity to expand on the gains made by Adaptive Statistical Iterative Reconstruction (ASiR),” said Dr. Jonathon Leipsic, Head of Radiology, Providence Health, St. Paul’s Hospital in Vancouver. “Veo has the potential to push radiation dose lower across organ systems while reducing image noise and improving spatial resolution – which would allow for more robust imaging of small structures and more confident assessment of heavily calcified arteries, an ongoing challenge in CT angiography.”
After decades of CT image reconstruction using filtered back projection and more recent advances in statistical raw data-based iterative reconstruction, such as GE’s powerful ASiR technology, Veo takes the next step by modeling the system itself and more complex data to help create outstanding clinical image quality at even lower dose levels.
“Given our proven history of CT imaging innovations, GE is proud to bring to market yet another innovative, patient-friendly technology in Canada,” said Peter Robertson, Vice President and General Manager of GE Healthcare Canada. “Veo can help clinicians and radiologists improve patient care by offering higher image quality and dramatically lower dose levels.”
GE Healthcare is helping coordinate a multi-centre study to investigate the improvements Veo may offer – including substantially lower dose levels – across a range of applications.
Developed in partnership with leading academic researchers and experts from GE’s Global Research Centre, Veo is available with the Discovery CT750 HD, a ‘healthymagination-certified’ product, meaning that it helps enable better healthcare for more people.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com
Posted July 28, 2011